Receive The Newest Study Notifications

- Phase II trial evaluating bemcentinib in combination with KEYTRUDA in advanced NSCLC patients shows 12-month survival data surpassing historical benchmarks in second-line treatment with PD-1 inhibitor monotherapy - Promising clinical activity continues to be seen,...

Clinical trials research develops safe and effective strategies to treat or prevent human disease and provide researchers with new ways to approach medical treatment that can improve or save the lives of patients. Historically, rural populations have been...

Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company...

The company will also present at the Jefferies 2019 Global Healthcare Conference MADRID, SPAIN and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2019 / Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging...

New patient-reported outcomes data shows trilaciclib improves chemotherapy experience for patients - G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today presented additional findings from a randomized Phase 2 clinical trial demonstrating the...

Initial experimental treatment arm results from NRG oncology trial suggests total neoadjuvant therapy for locally advanced rectal cancer is safe Results from the first experimental arm using veliparib as part of total neoadjuvant therapy (induction chemotherapy...

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today presented monotherapy data from the dose escalation portion of the Phase 1a/1b clinical...

Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring MET exon-14 skipping mutation  Overall response rate among...

IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that investigators shared new positive data for its DeCidE1 (DPX-Survivac with low dose Cyclophosphamide and Epacadostat) clinical trial at the 2019 American Society for...

Trial in Progress Poster to be Presented Today at the 2019 American Society of Clinical Oncology Annual Meeting Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today...

Massive Bio, Inc., a leader in precision medicine and patient centric clinical trial matching, announces today its partnership in the Biden Cancer Initiative’s Oncology Clinical Trial Information Commons (OCTIC). OCTIC is a shared platform where all information about...

TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 American Society of Clinical Oncology (ASCO) annual meeting,...

New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration Data 2019 ASCO Annual Meeting – Cellworks Group, Inc., a leader in Precision Medicine and a global pioneer of Therapy Response Index (TRI) technology, today announced the Cellworks...

  TM-B1 demonstrates 80% accuracy vs. 50% accuracy for current gold standard Todos Medical to attend 2019 ASCO Annual Meeting in Chicago, IL REHOVOT, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (TOMDF) (http://www.Todosmedical.com) today...

Kymab Presents Poster Detailing Adaptive Phase 1/2 Clinical Trial for its KY1044 Anti-ICOS Program at ASCO 2019 Annual Meeting -- Clinical trial initiated in February 2019 in the U.S.,MD Anderson Cancer Center and Sarah Cannon Research Institute -- Phase 1/2, open...

ALX Oncology, a clinical-stage immuno-oncology company developing therapies to block the CD47 myeloid checkpoint mechanism, today announced new results from its Phase 1 ALX148 solid tumor program at the 2019 ASCO Annual Meeting [ Abstract #2514 ]. As of April 18,...

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that the Stanford University School of Medicine will serve as the second contracted...

Follow-Up Data From The Phase I Trial Of DCVax®-Direct, and Progress Report On The Road To Unblinding The DCVax®-L Phase III GBM Trial Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid...

Poster presentation tomorrow, June 1st at 8:00 am CT in Poster Hall A Conference call and webcast to discuss results Monday, June 3rd at 8:30 am ET CAMBRIDGE, Mass., May 31, 2019 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company...

Interim results of a large, multicenter trial to be presented at ASCO Annual Meeting For patients with operable non-small cell lung cancer (NSCLC), pre-surgical "neoadjuvant" treatment with an immune checkpoint inhibitor was well tolerated and, in many cases, caused...